Pre-market JPX: 4582.T SymBio Pharmaceuticals JPY 171.00 24 Feb 2026: 77.39M vol
4582.T stock is trading in the pre-market on JPX at JPY 171.00, driven by an outsized volume of 77,393,100.00 shares. Traders note a gap open from JPY 136.00 and a day range of JPY 129.00–171.00. This most-active listing on the Japan exchange shows price above its 50-day average JPY 90.90 and 200-day average JPY 133.49, signalling momentum in early trading. We analyse fundamentals, technicals, pipeline catalysts, and short-term forecasts to explain the activity and what it could mean for intraday and swing strategies.
Pre-market snapshot for 4582.T stock
SymBio Pharmaceuticals (4582.T) is trading pre-market on the JPX at JPY 171.00 with a reported volume of 77,393,100.00, versus an average volume of 908,683.00. The stock opened at JPY 136.00, previous close was JPY 171.00, day low JPY 129.00 and day high JPY 171.00. Relative volume is elevated at 92.15, flagging outsized order flow early in the session.
Fundamentals and valuation for 4582.T stock
SymBio shows stretched valuation metrics against sector peers. Key figures: EPS -95.12, P/E -1.68, price-to-sales 5.97, price-to-book 6.32, cash per share JPY 57.43, and book value per share JPY 25.33. Debt-to-equity sits at 1.56 and current ratio is 2.96, indicating liquidity but higher leverage than the healthcare sector average debt-to-equity of 0.60. The elevated P/S and P/B relative to sector averages point to investor pricing of pipeline value rather than current earnings.
Clinical pipeline and catalysts driving 4582.T stock interest
SymBio’s marketed product TREAKISYM and its late-stage pipeline are central catalysts. The company runs Phase III trials for SyB L-1101 (HR-MDS) and a Phase III program for relapsed/refractory DLBCL for Treakisym variants. Ongoing readouts, regulatory steps, or partnership announcements can move 4582.T stock materially. Near-term news windows include study milestones and the scheduled earnings announcement on 2026-05-07.
Technical setup and momentum on 4582.T stock
Technicals show strong short-term momentum and overbought signals. RSI is 81.73, MACD histogram is 8.69, ADX is 27.59, and MFI is 99.33, indicating heavy buying pressure. Price sits above the 50-day JPY 90.90 and 200-day JPY 133.49 moving averages, with Bollinger upper band at JPY 145.16, suggesting the stock is extended intraday. Traders should expect volatility given ATR 13.08 and a performance surge of 53.85% over three months.
Risks, sector context and analyst signals for 4582.T stock
Downside risks include negative earnings, long development timelines and leverage. SymBio reports net income pressure and an interest coverage ratio of -29.71, while the company rating on 2026-02-20 shows a D+ with a Strong Sell recommendation from one data source. The healthcare sector on JPX has an average P/E of 23.41, so 4582.T’s negative earnings and high P/S create valuation risk if pipeline milestones disappoint.
Meyka AI grade and model forecast for 4582.T stock
Meyka AI rates 4582.T with a score out of 100: 64.10 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of JPY 68.94 and a quarterly target of JPY 20.03. Compared with the current price JPY 171.00, the monthly projection implies a model-based downside of -59.68% and the quarterly projection implies -88.31%. Forecasts are model-based projections and not guarantees.
Final Thoughts
4582.T stock is attracting pre-market attention on JPX because of a very large volume surge and price trading above short- and long-term averages. The setup shows clear momentum but also large overbought signals: RSI 81.73 and MFI 99.33. Fundamentals remain mixed — strong cash per share JPY 57.43 but negative EPS -95.12 and elevated leverage. For active traders, the most actionable factors are the volume spike and technical breakout above the 200-day average JPY 133.49. For investors, the key questions are trial readouts and commercial uptake of TREAKISYM and late-stage candidates. Meyka AI’s model projects a monthly level of JPY 68.94, implying material downside versus the current price; use that as a risk-check rather than a timing signal. We note the company is listed on JPX in Japan and recommend close monitoring of news flow and liquidity before adding exposure.
FAQs
What drove the pre-market move in 4582.T stock today?
The pre-market move in 4582.T stock was driven by a large volume spike of 77,393,100.00 shares, a gap open and price trading above the 50-day and 200-day moving averages. Early trading suggests momentum-based orders rather than a visible single news item.
How does SymBio’s valuation compare to its healthcare peers for 4582.T stock?
4582.T stock shows higher price-to-sales 5.97 and price-to-book 6.32 versus healthcare sector averages, while EPS is negative -95.12, indicating the market is pricing future pipeline value rather than current earnings.
What is Meyka AI’s short-term forecast for 4582.T stock?
Meyka AI’s forecast model projects a monthly level of JPY 68.94 for 4582.T stock. This is a model-based projection and implies downside versus the current JPY 171.00 price; forecasts are not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.